11.1 Focused Antenatal Care & Routine ANC Screening

Focused Antenatal Care & Routine ANC Screening

Antenatal care (ANC) serves as the primary gateway for identifying, mitigating, and treating life-threatening maternal and fetal complications. The Kenya Ministry of Health (MOH) has transitioned from the traditional 4-visit Focused Antenatal Care (FANC) model to the comprehensive 8-contact Antenatal Care model aligned with the 2016 World Health Organization (WHO) recommendations. This expanded framework shifts the clinical paradigm from passive risk categorization to proactive, continuous maternal-fetal surveillance, evidence-based preventive therapies, and positive pregnancy experiences.

For clinical officers appearing for the Clinical Officers Council (COC) Pre-Internship Examination, mastery of the 8-contact schedule, first-contact laboratory screening panels, Rhesus alloimmunization protocols, nutritional supplementation regimens, and malaria chemoprophylaxis is essential for both examination success and primary healthcare delivery.

---

1. The Kenya 8-Contact Antenatal Care Schedule

The 8-contact model increases maternal-provider contact points throughout gestation, substantially reducing stillbirths, undetected pre-eclampsia, fetal growth restriction, and preventable maternal mortality. Early contact is vital: booking before 12 weeks allows accurate gestational dating by early ultrasound, early screening for hemoglobinopathies and chronic medical conditions, and prompt initiation of prophylactic interventions.

Individualized Birth Plan (IBP)

Every pregnant woman must formulate an actionable birth and emergency complication readiness plan during early ANC contacts, documented in the Mother-Child Health (MCH) booklet:

1. Identified Delivery Facility: Level 3 health center or Level 4/5 hospital with 24-hour skilled delivery services.
2. Skilled Attendant: Delivery assisted by a registered clinical officer, medical officer, or registered midwife.
3. Emergency Transport: Concrete arrangement for round-the-clock motorized transit in the event of emergency onset or labor.
4. Emergency Funds: Dedicated household savings for transport, medicines, or emergency interventions.
5. Designated Birth Companion: Trusted family member or partner to accompany the mother during labor.
6. Identified Compatible Blood Donor: Designated blood donors screened and available in case of severe obstetric hemorrhage.

---

2. Mandatory First-Contact Baseline Laboratory Screening

At the initial antenatal booking contact (< 12 weeks), every woman must undergo a core profile of mandatory diagnostic investigations. Skipping these baseline tests places both mother and fetus at profound risk of unmonitored decompensation.

MANDATORY FIRST-CONTACT SCREENING PANEL:

1. Blood Group & Rhesus Factor Determination
   • Identifies Rh-negative status to prevent hemolytic disease of the fetus and newborn (HDFN).

2. Complete Blood Count / Hemoglobin (Hb) Level
   • Establishes baseline hematological status; threshold for anemia is Hb < 11.0 g/dL.

3. Rapid Dual HIV / Syphilis Serological Testing
   • Point-of-care rapid immunochromatographic test (one finger-prick drop of blood).
   • Immediate PMTCT triple ART for HIV; immediate Benzathine Penicillin G for syphilis.

4. Routine Dipstick Urinalysis & Microscopy
   • Detects asymptomatic bacteriuria (nitrites, leukocyte esterase) and baseline proteinuria.

5. Random or Fasting Blood Glucose
   • Unmasks undiagnosed pre-existing overt diabetes mellitus in early pregnancy.

Rhesus Blood Grouping & Alloimmunization Prophylaxis

When an Rh-negative mother carries an Rh-positive fetus, feto-maternal hemorrhage during pregnancy or delivery allows fetal D-antigen-positive red blood cells to enter the maternal circulation. The maternal immune system recognizes the D antigen as foreign, generating anti-D antibodies (isoimmunization). In subsequent Rh-positive pregnancies, maternal IgG anti-D antibodies cross the placenta, causing immune-mediated fetal hemolysis, severe fetal anemia, hydrops fetalis, and intrauterine death.

• Screening: Blood group and Rhesus status at first contact. If Rh-negative, perform an Indirect Coombs Test (ICT) to assess whether sensitization has already occurred.
• Unsensitized Rh-Negative Mother (ICT Negative):
  • Routine Antenatal Prophylaxis: Administer Anti-D Immunoglobulin 300 mcg (1500 IU) IM routinely at 28 weeks of gestation (or a split-dose protocol of 100–150 mcg at 28 and 34 weeks).
  • Postpartum Prophylaxis: Administer a second dose of Anti-D Immunoglobulin 300 mcg IM within 72 hours of delivery if the newborn is confirmed to be Rh-positive with a negative Direct Coombs Test.
  • Sensitizing Events: Administer Anti-D 300 mcg IM within 72 hours of ANY potential feto-maternal hemorrhage occurring after 12 weeks (miscarriage, ectopic pregnancy, therapeutic abortion, chorionic villus sampling, amniocentesis, antepartum hemorrhage, blunt abdominal trauma, external cephalic version). If before 12 weeks, a mini-dose of 50–100 mcg IM is acceptable.
  • Kleihauer-Betke Test: Indicated in major obstetric hemorrhage or severe trauma to quantify feto-maternal transfusion and calculate additional vials of Anti-D needed (each 300 mcg vial neutralizes up to 30 mL of fetal whole blood or 15 mL of fetal packed red cells).

Maternal Syphilis Screening & Management

Syphilis in pregnancy causes devastating outcomes: spontaneous abortion, stillbirth (up to 40%), non-immune hydrops fetalis, preterm delivery, and congenital syphilis (snuffles, hepatosplenomegaly, osteochondritis, saber shins, Hutchinson triad). Universal point-of-care screening using a rapid dual HIV/syphilis antibody test is mandatory at the first visit.

• Confirmed Syphilis Treatment (Kenya National Guidelines):
  • Benzathine Penicillin G: 2.4 million units IM administered as two divided injections of 1.2 million units in each buttock, weekly for 3 consecutive weeks (total dose = 7.2 million units) for late latent syphilis or syphilis of unknown duration/stage.
  • Early Primary / Secondary Syphilis: A single dose of 2.4 million units IM is acceptable, though many clinicians provide 2–3 doses to ensure complete eradication.
  • Penicillin Allergy: Erythromycin or azithromycin can be used in non-pregnant patients, but macrolides do not cross the placenta reliably to treat the fetus. In pregnant women with confirmed penicillin allergy, the gold-standard recommendation is inpatient penicillin desensitization followed by full therapeutic Benzathine Penicillin G.
  • Partner Management: Sexual partners must be treated simultaneously to prevent maternal re-infection.
  • Jarisch-Herxheimer Reaction: Inform the patient that acute fever, headache, tachycardia, and uterine contractions may occur within 2 to 12 hours of the first penicillin injection due to massive spirochete lysis; managed supportively with paracetamol and monitoring.

Maternal HIV Testing & Elimination of Mother-to-Child Transmission (eMTCT)

• Testing Protocol: Opt-out Provider-Initiated Testing and Counseling (PITC) at Contact 1. For women who test HIV-negative, repeat testing is mandatory at 32–36 weeks of gestation, during active labor/delivery, and at 6 weeks postpartum.
• Treatment: Any pregnant woman testing HIV-positive must be initiated on immediate, lifelong antiretroviral therapy (ART) on the same day, regardless of CD4 count or WHO clinical stage. First-line regimen in Kenya is TLD: Tenofovir Disoproxil Fumarate (300 mg) + Lamivudine (300 mg) + Dolutegravir (50 mg) once daily.
• Viral Load Monitoring: Check viral load at 3 months post-initiation and every 6 months until cessation of breastfeeding. The clinical goal is undetectable viral load (< 50 copies/mL) to eliminate vertical transmission during vaginal delivery and breastfeeding.

---

3. Routine Prophylactic & Nutritional Regimens

Pregnancy imposes high physiological demands for micronutrients to support maternal erythrocyte mass expansion, fetoplacental development, and skeletal mineralization.

ROUTINE ANTENATAL PROPHYLAXIS PROTOCOL:

[First Contact (<12 Weeks)]
  ├── IFAS: 60 mg elemental iron + 400 mcg folic acid daily (throughout gestation)
  ├── Tetanus-Diphtheria (Td/TT): First dose (Td1) at first contact
  └── Long-Lasting Insecticidal Net (LLIN): Issued free of charge

[Second Trimester (≥13 Weeks / From 20 Weeks)]
  ├── IPTp-SP: First dose at start of 2nd trimester (≥13 weeks); repeat every ≥4 weeks
  ├── Calcium Supplementation: 1.5–2.0 g daily in divided doses (start at 20 weeks)
  ├── Deworming: Albendazole 400 mg single dose at Contact 2 (after 1st trimester)
  └── Td2: Administer 4 weeks after Td1 (confers 3 years protection)

Iron & Folic Acid Supplementation (IFAS)

• Daily Composition: One fixed-dose combination tablet containing 60 mg elemental iron (e.g., 200 mg dried ferrous sulfate or 180 mg ferrous fumarate) plus 400 mcg (0.4 mg) folic acid.
• Clinical Timing: Commenced at the first contact and continued daily throughout pregnancy and for at least 6 months postpartum.
• Clinical Rationale: Prevents maternal iron deficiency anemia, reduces preterm birth and low birth weight, and prevents fetal neural tube defects (spina bifida, anencephaly).
• Patient Counseling: Advise the mother that iron can cause black/dark stools, mild nausea, and constipation. Tablets should be taken with clean water or vitamin C-rich fruit juice to enhance absorption. Advise her to avoid taking iron concurrently with tea, coffee, milk, antacids, or calcium supplements, which chelate iron and severely inhibit intestinal absorption (maintain at least a 2-hour separation).

Calcium Supplementation

• Dosage & Protocol: 1.5 g to 2.0 g elemental calcium daily, administered orally in three divided doses of 500 mg with meals, starting from 20 weeks of gestation until delivery.
• Indication: Recommended by WHO and Kenya MOH for all pregnant women, particularly in areas with low dietary calcium intake, to significantly reduce the risk of gestational hypertension, pre-eclampsia, and preterm delivery.
• Drug Separation: Calcium competitively inhibits iron absorption; never administer calcium and IFAS tablets at the same time. Instruct patients to take IFAS in the morning and calcium with afternoon and evening meals.

Tetanus Toxoid / Td Vaccination Schedule

Maternal and neonatal tetanus carries a near 100% case fatality rate in unimmunized home births. Protection is achieved through the 5-dose Td (Tetanus-Diphtheria) schedule for women of reproductive age:

---

4. Malaria Prophylaxis in Pregnancy

Plasmodium falciparum parasites selectively sequester in the maternal placental intervillous spaces by binding chondroitin sulfate A (CSA). Placental malaria compromises nutrient and oxygen transfer, causing severe maternal anemia, intrauterine growth restriction (IUGR), low birth weight (< 2500 g), miscarriage, and neonatal mortality.

Intermittent Preventive Treatment with Sulfadoxine-Pyrimethamine (IPTp-SP)

In high-transmission malaria zones in Kenya (Lake Endemic counties such as Kisumu, Siaya, Homa Bay, Migori, Busia, Kakamega, and Coastal Endemic counties such as Kilifi, Kwale, Mombasa), IPTp-SP is a core intervention:

• Timing: Initiate at the start of the second trimester (from 13 weeks of gestation or upon first maternal perception of fetal movement [quickening]). Never administer SP in the first trimester (< 13 weeks) due to potential teratogenicity.
• Dosage & Administration: Each dose consists of 3 tablets of fixed-dose Sulfadoxine (500 mg) + Pyrimethamine (25 mg), giving a total single dose of 1500 mg Sulfadoxine / 75 mg Pyrimethamine. Must be administered as Directly Observed Therapy (DOT) in the clinic under the clinical officer's supervision.
• Frequency: Administered at every scheduled ANC contact from 13 weeks onwards, with each dose spaced at least 4 weeks (1 month) apart, up to the time of delivery. A woman should receive a minimum of 3 doses during pregnancy.
• Critical Drug-Nutrient Interaction: High-dose folic acid (≥ 5 mg daily) competitively antagonizes pyrimethamine's inhibition of parasite dihydrofolate reductase, neutralizing SP antimalarial efficacy. Therefore, high-dose folic acid (5 mg) is strictly contraindicated when receiving IPTp-SP. Standard ANC IFAS tablets (containing 400 mcg / 0.4 mg folic acid) contain low-dose folate that does not undermine SP efficacy and must be continued.
• Absolute Contraindications:
  1. Known hypersensitivity to sulfonamides or pyrimethamine (risk of Stevens-Johnson syndrome or toxic epidermal necrolysis).
  2. HIV-positive pregnant women receiving daily Co-trimoxazole Preventive Therapy (CPT): Co-trimoxazole already provides adequate protection against malaria, toxoplasmosis, and bacterial infections. Co-administering SP with co-trimoxazole markedly increases the risk of severe sulfonamide toxicity and is contraindicated.